Ftse Mib
33.736,40
-0,03%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.464,12
0,58%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cullinan Therapeutics Inc (CGEM) Cullinan Therapeutics Inc (CGEM) Notizie

Cullinan Therapeutics Inc

CGEM
27,89
-0,21 (-0,75%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202413:00GLOBECullinan Therapeutics Announces Appointment of Mary Kay..
24/4/202416:09GLOBECullinan Therapeutics to Present Clinical Data from Phase 1..
16/4/202413:00GLOBECullinan Therapeutics Announces Strategic Expansion into..
16/4/202412:59GLOBECullinan Therapeutics Announces Oversubscribed $280 million..
14/3/202412:00GLOBECullinan Oncology Provides Corporate Update and Reports..
01/3/202413:00GLOBECullinan Oncology Announces U.S. FDA Clearance of..
27/2/202414:00GLOBECullinan Oncology to Participate in Upcoming Investor..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202403:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
03/2/202403:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202422:43EDGAR2Form 144 - Report of proposed sale of securities
31/1/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202422:27EDGAR2Form 144 - Report of proposed sale of securities
24/1/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202422:18EDGAR2Form 144 - Report of proposed sale of securities
08/1/202422:15EDGAR2Form 8-K/A - Current report: [Amend]
08/1/202415:12EDGAR2Form 8-K - Current report
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202300:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:53GLOBECullinan Oncology to Present at the 42nd Annual J.P. Morgan..
14/12/202322:30GLOBECullinan Oncology Announces First Patient Dosed in Phase 1..
14/12/202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202313:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:10EDGAR2Form 8-K - Current report
08/11/202313:00GLOBECullinan Oncology Provides Corporate Update and Reports..
03/11/202317:01GLOBECullinan Oncology to Present Data Demonstrating Progress..
30/10/202313:00GLOBECullinan Oncology to Participate in Upcoming Investor..
06/9/202314:00GLOBECullinan Oncology to Participate in Upcoming Investor..
10/8/202313:44EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202313:07EDGAR2Form 8-K - Current report
10/8/202313:00GLOBECullinan Oncology Provides Corporate Update and Reports..
09/8/202313:00GLOBECullinan Oncology Announces First Patient Dosed in Phase 1..
03/8/202322:15PRNUSREZILIENT3 Global First-Line Trial of Zipalertinib Launched..
31/7/202314:00GLOBECullinan Oncology to Participate in Upcoming Investor..
06/7/202303:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/5/202323:00GLOBECullinan Oncology to Present First Monotherapy Clinical Data..
11/5/202322:01GLOBECullinan Oncology Provides Corporate Update and Reports..
Apertura: 28,22 Min: 26,73 Max: 28,22
Chiusura: 28,10

La tua Cronologia

NASDAQ
CGEM
Cullinan Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network